Dr. Ben Yiming Zhang, MD

Dr. Zhang practices at Minnesota Oncology Hematology, PA in Burnsville, Minnesota.

Dr. Zhang's NPI, 1366738098, was assigned on June 21, 2011. Dr. Zhang graduated from University of Texas Medical School at Houston in 2011. Dr. Zhang holds Minnesota license 55527.

Dr. Zhang's primary practice is Minnesota Oncology Hematology, PA, at 675 Nicollet E Blvd, Burnsville, MN 55337 in Dakota County. The practice phone is (952) 892-7190.

Dr. Zhang's primary practice is Minnesota Oncology Hematology, PA in Burnsville, Minnesota. Dr. Zhang is also affiliated with M Health Fairview Ridges Hospital. The medical group on file is Minnesota Oncology. Dmand AI also links Dr. Zhang to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zhang practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zhang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Zhang is licensed in Minnesota.

CMS data shows 53,241 Medicare services from Dr. Zhang across 52 procedure codes in 2024, for 389 Medicare patients. Medicare paid $1,198,035 for them.

CMS counts 389 Medicare patients who saw Dr. Zhang in 2024. The largest group is 75 to 84, with 156 patients. 72% of them have high blood pressure, and 65% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zhang's median patient age at 67, with 53% women.

In 2024, Dr. Zhang wrote 1,973 Medicare Part D claims for 250 patients. 70% of them were for generic drugs. CMS names the drug for 1,640 of them, across 47 drugs with 11 or more claims each, at $6,715,263 in total drug cost. In 2023, CMS named 1,273 claims across 43 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Zhang for performance year 2024, reported through an alternative payment model (APM). Dr. Zhang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zhang as offering telehealth.

Dmand AI links 7 papers to Dr. Zhang, published from 2012 to 2017. 2016 was the busiest year, with 3. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Neoplasm Grading. Dr. Zhang's most frequent co-authors are Brian A. Costello, MD, Manish Kohli, MD and Stephen Anthony Boorjian, MD.

CMS Open Payments shows 18 general payments to Dr. Zhang from 10 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 79% of the total. Merck Sharp & Dohme Corporation paid the most, $2,579.

Dr. Zhang graduated from University of Texas Medical School at Houston in 2011.